NCT05154487 - A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2026

Conditions

Endometroid Endometrial Cancer

Interventions

DRUG

Alpelisib Pill

Kinase inhibitor

DRUG

Fulvestrant injection

estrogen receptor agonist

Trial Locations (11)

21287

RECRUITING

Johns Hopkins Medicine, Baltimore

32804

RECRUITING

AdventHealth Gynecologic Oncology, Orlando

33606

RECRUITING

Tampa General Hospital, Tampa

45429

RECRUITING

Kettering Health Cancer Center, Kettering

46260

RECRUITING

Ascension St. Vincent, Indianapolis

53792

RECRUITING

University of Wisconsin Clinical Science Center, Madison

74146

RECRUITING

Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa

91010

RECRUITING

City of Hope, Duarte

97062

RECRUITING

Legacy Meridian Park Medical Center, Tualatin

97210

RECRUITING

Legacy Good Samaritan Medical Center, Portland

98686

RECRUITING

Legacy Salmon Creek Medical Center, Vancouver